Balaxi Pharmaceuticals Ltd
Balaxi Pharmaceuticals Ltd is an IPR-based pharmaceutical Company engaged in producing, stocking, selling, and supplying branded and generic medicines. [1]
- Market Cap ₹ 627 Cr.
- Current Price ₹ 575
- High / Low ₹ 686 / 400
- Stock P/E 76.8
- Book Value ₹ 95.3
- Dividend Yield 0.00 %
- ROCE 29.8 %
- ROE 23.2 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 87.3% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 29.5%
Cons
- Company has high debtors of 264 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0.19 | 0.05 | 0.14 | 0.12 | 0.05 | 0.00 | 0.00 | 13.60 | 45.63 | 86.87 | 101.29 | 108.14 | 84.64 | |
0.05 | 0.02 | 0.03 | 0.08 | 0.11 | 0.13 | 0.77 | 12.05 | 36.98 | 67.85 | 83.99 | 91.26 | 74.27 | |
Operating Profit | 0.14 | 0.03 | 0.11 | 0.04 | -0.06 | -0.13 | -0.77 | 1.55 | 8.65 | 19.02 | 17.30 | 16.88 | 10.37 |
OPM % | 73.68% | 60.00% | 78.57% | 33.33% | -120.00% | 11.40% | 18.96% | 21.89% | 17.08% | 15.61% | 12.25% | ||
0.00 | 0.03 | 0.05 | 0.12 | 0.00 | 0.00 | 0.00 | 0.89 | 0.59 | 1.81 | 2.75 | 6.60 | 2.49 | |
Interest | 0.00 | 0.00 | 0.01 | 0.01 | 0.05 | 0.04 | 0.00 | 0.00 | 0.05 | 0.15 | 0.10 | 0.51 | 1.26 |
Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.09 | 0.25 | 0.52 | 0.66 |
Profit before tax | 0.14 | 0.06 | 0.15 | 0.15 | -0.11 | -0.17 | -0.77 | 2.44 | 9.18 | 20.59 | 19.70 | 22.45 | 10.94 |
Tax % | 14.29% | 16.67% | 26.67% | 26.67% | 36.36% | 0.00% | 0.00% | 19.26% | 29.30% | 26.52% | 25.53% | 27.75% | |
0.12 | 0.04 | 0.11 | 0.10 | -0.08 | -0.17 | -0.77 | 1.97 | 6.50 | 15.13 | 14.67 | 16.22 | 8.16 | |
EPS in Rs | 1.57 | 0.33 | -0.26 | -0.56 | -2.53 | 6.48 | 6.50 | 15.13 | 14.67 | 15.93 | 7.99 | ||
Dividend Payout % | 58.33% | 175.00% | 63.64% | 91.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3.41% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 116% |
5 Years: | % |
3 Years: | 33% |
TTM: | -14% |
Compounded Profit Growth | |
---|---|
10 Years: | 82% |
5 Years: | 87% |
3 Years: | 36% |
TTM: | -50% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 45% |
3 Years: | -1% |
1 Year: | 9% |
Return on Equity | |
---|---|
10 Years: | 29% |
5 Years: | 31% |
3 Years: | 29% |
Last Year: | 23% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 0.70 | 0.70 | 0.70 | 3.04 | 3.04 | 3.04 | 3.04 | 3.04 | 10.00 | 10.00 | 10.00 | 10.18 | 10.23 |
Reserves | 0.08 | 0.05 | 0.08 | 0.18 | 0.11 | -0.72 | -1.49 | 0.48 | 18.11 | 33.25 | 47.91 | 71.63 | 87.27 |
0.22 | 0.16 | 0.18 | 0.00 | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 3.51 | 1.93 | 12.43 | 20.04 | |
0.18 | 0.33 | 0.24 | 0.46 | 0.22 | 0.05 | 0.13 | 2.59 | 9.79 | 22.16 | 22.07 | 35.48 | 24.26 | |
Total Liabilities | 1.18 | 1.24 | 1.20 | 3.68 | 3.57 | 2.37 | 1.68 | 6.11 | 37.90 | 68.92 | 81.91 | 129.72 | 141.80 |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.19 | 0.69 | 2.20 | 7.89 | 10.53 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.57 | 2.83 | 0.00 |
Investments | 0.48 | 0.47 | 0.19 | 3.42 | 3.29 | 0.00 | 0.00 | 0.00 | 0.10 | 19.54 | 19.61 | 19.54 | 19.54 |
0.70 | 0.77 | 1.01 | 0.26 | 0.28 | 2.37 | 1.67 | 6.10 | 37.61 | 48.69 | 59.53 | 99.46 | 111.73 | |
Total Assets | 1.18 | 1.24 | 1.20 | 3.68 | 3.57 | 2.37 | 1.68 | 6.11 | 37.90 | 68.92 | 81.91 | 129.72 | 141.80 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.32 | -0.24 | 0.21 | -0.03 | -0.13 | -0.68 | -1.51 | -14.37 | 13.46 | 8.89 | -7.07 | |
0.33 | -0.05 | 0.32 | -3.11 | 0.13 | 2.67 | -0.01 | -0.01 | -0.28 | -20.03 | -6.87 | -2.29 | |
0.20 | -0.29 | -0.07 | 2.38 | -0.11 | -0.24 | 0.00 | 0.00 | 18.10 | 3.49 | -1.64 | 26.39 | |
Net Cash Flow | 0.53 | -0.02 | 0.01 | -0.52 | -0.02 | 2.30 | -0.69 | -1.51 | 3.44 | -3.08 | 0.38 | 17.03 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 0.00 | 219.00 | 756.07 | 30.42 | 0.00 | 146.81 | 249.73 | 202.23 | 187.78 | 264.25 | ||
Inventory Days | 9.23 | 0.12 | 0.00 | 6.62 | ||||||||
Days Payable | 81.27 | 95.96 | 76.73 | |||||||||
Cash Conversion Cycle | 0.00 | 219.00 | 756.07 | 30.42 | 0.00 | 146.81 | 177.69 | 106.38 | 187.78 | 194.14 | ||
Working Capital Days | -76.84 | -1,825.00 | 573.57 | -669.17 | 73.00 | 82.12 | 186.70 | 109.37 | 112.43 | 192.59 | ||
ROCE % | 8.05% | 6.28% | 17.11% | 7.66% | -1.83% | -4.59% | -39.79% | 96.25% | 58.36% | 55.40% | 37.15% | 29.80% |
Documents
Announcements
Annual reports
Concalls
-
May 2023TranscriptNotesPPT
-
Jan 2023TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Aug 2022TranscriptPPT
-
Jun 2022TranscriptNotesPPT
-
Jan 2021TranscriptPPT
Product Portfolio
Balaxi Pharmaceuticals Limited has a rich portfolio of 610 pharmaceutical product registrations. The pharma product portfolio of the company includes Tablets (46%), Injectables(17%), Liquids (12%), Capsules (13%), and Others (12%). The pharma products are sourced from WHO-GMP certified contract manufacturers based in India, China, and Portugal. [1] [2] [3]